Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
City of Hope Medical Center, Duarte, California, United States
Stanford University School of Medicine, Stanford, California, United States
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center, Fullerton, California, United States
Sansum Medical Clinic, Santa Barbara, California, United States
Local Institution, Austin, Texas, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States
University Hospital of Crete, Heraklion, Crete, Greece
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
Department of Medical Oncology, "Marika Iliadis" Hospital of Athens, Athens, Greece
Investigational Site Number, Madison, Wisconsin, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.